Title:
選択的活性エストロゲンとしての9-α置換のエストラトリエン
Document Type and Number:
Japanese Patent JP4615998
Kind Code:
B2
Abstract:
The invention relates to novel 9 alpha -substituted estratrienes of general formula (I) - wherein R3, R7, R7', R13, R16, R17 and R17' have the designations cited in the description, and R9 represents a linear-chain or branched-chain, optionally partially or fully halogenated alkenyl radical comprising between 2 and 6 carbon atoms, or an ethinyl radical or a prop-1-inyl radical - as pharmaceutical active ingredients which have, in vitro, a higher affinity to estrogen receptor preparations of the rat prostate than to estrogen receptor preparation of the rat uterus, and, in vivo, preferably a preferential action on the ovary compared to the uterus. The invention also relates to the production of said estratrienes, to the therapeutic application thereof and to pharmaceutical forms of administration containing the novel compounds. The invention further relates to the use of said compounds for treating illnesses and states related to estrogen deficiency.
Inventors:
Dirk, Kosemund
Mueller, Gerd
Hirish, alexander
Fritzheimer, Karl-Heinrich
Moon, peter
Mueller, Gerd
Hirish, alexander
Fritzheimer, Karl-Heinrich
Moon, peter
Application Number:
JP2004511321A
Publication Date:
January 19, 2011
Filing Date:
June 11, 2003
Export Citation:
Assignee:
Bayer Schering Pharma Aktiengesellschaft
International Classes:
A61K31/4535; C07J1/00; A61K31/565; A61P5/30; A61P13/08; A61P15/00; A61P19/10; A61P25/00; A61P29/00; A61P37/04; A61P37/06; C07J41/00; C07J63/00
Domestic Patent References:
| JP50047966A |
Foreign References:
| WO2001077138A1 | ||||
| WO2001032680A1 | ||||
| WO2000001073A1 |
Attorney, Agent or Firm:
Atsushi Aoki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Kazuhiro Nakamura
Masaya Nishiyama
Takashi Ishida
Fukumoto product
Tetsuji Koga
Kazuhiro Nakamura
Masaya Nishiyama